Alexander Spira, MD, PhD, FACP, Discusses Impacts of COVID-19 at Individual Treatment Facilities

Video

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about COVID-19 and immediate changes that took place during the pandemic.

At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Alexander Spira, MD, PhD, FACP, of Virginia Cancer Specialists, about how COVID-19 drastically changed his institution and what has been implemented to keep providers and patients safe.

Transcript:

COVID-19 has really changed how we think and how we’ve done everything. We never closed [my institution], but we did a lot of telemedicine visits; we still are, but not as much as before. [COVID-19 has] affected everything from our research program to our patients. Most importantly, it’s affected the patients because we’ve limited visitors for obvious reasons. This has been a harder time for the patients and their loved ones to not have somebody with them when they’re in clinic getting their infusion. We’ve all at this point become accustomed to it. We’re all masked up, I’ve got mine sitting right next to me. It’s just been tough and challenging. We’ve all evolved [but] it’ll be great to get back to normal at some point, though.

Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content